文献速递临床试验与 GCP

RECOVERY试验数据监查委员会的经验:一项针对COVID-19住院患者治疗的大规模适应性平台随机试验

Experiences of the Data Monitoring Committee for the RECOVERY trial, a large-scale adaptive platform randomised trial of treatments for patients hospitalised with COVID-19.
PubMed 文献 · Trials · 2022-10-18

本文总结RECOVERY试验数据监查委员会(DMC)在2020年3月至2022年2月期间的经验。DMC监管了成人14种治疗(儿童10种)、超过45000例随机患者的数据。关键要素包括大型委员会、明确规划与沟通、快速招募与电子健康记录链接、与监管机构建设性合作及视频会议。挑战包括前四种治疗竞争患者、平衡全球健康需求与保密性、可靠评估安全性。

要点

  • DMC由具有丰富DMC经验和广泛临床专业知识的成员组成大型委员会。
  • 试验主研究者进行清晰战略规划、沟通并及时响应。
  • 数据收集与分析系统能应对快速招募期并与电子健康记录链接。

核心结论

  • RECOVERY简化的适应性平台设计与医院级和人群级健康数据链接,使能快速可靠评估多种COVID-19住院患者治疗。
  • 后期引入析因评估提高了试验效率,且未损害DMC评估安全性和有效性的能力。
  • 在数据不成熟时监管机构要求释放非盲主要结局数据,需要DMC与监管机构大量沟通以避免不适当的早期试验终止。

研究设计与样本

  • RECOVERY是一项大规模随机适应性平台临床试验,评估COVID-19住院患者的治疗。
  • 试验前24个月(2020年3月至2022年2月)内,DMC监管了成人14种治疗(儿童10种)的数据,涉及超过45000例随机患者。

主要发现

  • DMC有效运作的关键方面包括:大型委员会、主研究者的清晰战略规划与沟通、能应对快速招募的数据系统、与监管机构建设性合作、以及视频会议系统的使用。
  • 挑战包括:前四种治疗实际上在竞争患者,增加了对每种治疗快速决策的压力;平衡报告发现的全球健康 imperative 与在结果足够确定前保持保密的需要;可靠评估安全性,尤其是初始波后引入的新药及少数孕妇和儿童。
  • 文中通过案例 vignettes 说明了羟氯喹、地塞米松、卡西里维单抗+依米得韦单抗和托珠单抗相关的问题与DMC决策。

局限性

  • 挑战包括前四种治疗实际上在竞争患者,增加了对每种治疗快速决策的压力。
  • 需要平衡报告发现的全球健康 imperative 与在结果足够确定以适当指导治疗决策前保持保密的需要。
  • 可靠评估安全性存在挑战,尤其是对初始波后引入的新药以及少数孕妇和儿童。
  • 在数据不成熟时监管机构要求释放非盲主要结局数据,需要DMC与监管机构大量沟通以避免不适当的早期试验终止。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIM: To inform the oversight of future clinical trials during a pandemic, we summarise the experiences of the Data Monitoring Committee (DMC) for the Randomised Evaluation of COVID therapy trial (RECOVERY), a large-scale randomised adaptive platform clinical trial of treatments for hospitalised patients with COVID-19. METHODS AND FINDINGS: During the first 24 months of the trial (March 2020 to February 2022), the DMC oversaw accumulating data for 14 treatments in adults (plus 10 in children) involving > 45,000 randomised patients. Five trial aspects key for the DMC in performing its role were: a large committee of members, including some with extensive DMC experience and others who had broad clinical expertise; clear strategic planning, communication, and responsiveness by the trial principal investigators; data collection and analysis systems able to cope with phases of very rapid recruitment and link to electronic health records; an ability to work constructively with regulators (and other DMCs) to address emerging concerns without the need to release unblinded mortality results; and the use of videoconferencing systems that enabled national and international members to meet at short notice and from home during the pandemic when physical meetings were impossible. Challenges included that the first four treatments introduced were effectively 'competing' for patients (increasing pressure to make rapid decisions on each one); balancing the global health imperative to report on findings with the need to maintain confidentiality until the results were sufficiently certain to appropriately inform treatment decisions; and reliably assessing safety, especially for newer agents introduced after the initial wave and in the small numbers of pregnant women and children included. We present a series of case vignettes to illustrate some of the issues and the DMC decision-making related to hydroxychloroquine, dexamethasone, casirivimab + imdevimab, and tocilizumab. CONCLUSIONS: RECOVERY's streamlined adaptive platform design, linked to hospital-level and population-level health data, enabled the rapid and reliable assessment of multiple treatments for hospitalised patients with COVID-19. The later introduction of factorial assessments increased the trial's efficiency, without compromising the DMC's ability to assess safety and efficacy. Requests for the release of unblinded primary outcome data to regulators at points when data were not mature required significant efforts in communication with the regulators by the DMC to avoid inappropriate early trial termination.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Sandercock PAG, Darbyshire J, DeMets D, et al. Experiences of the Data Monitoring Committee for the RECOVERY trial, a large-scale adaptive platform randomised trial of treatments for patients hospitalised with COVID-19. Trials. 2022. PMID: 36258219. doi:10.1186/s13063-022-06824-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。